Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

The cost-utility of sodium oxybate as narcolepsy treatment

Artikel i vetenskaplig tidskrift
Författare Kristian Bolin
P. Berling
Pontus Wasling
H. Meinild
J. Kjellberg
P. Jennum
Publicerad i Acta Neurologica Scandinavica
Volym 136
Nummer/häfte 6
Sidor 715-720
ISSN 0001-6314
Publiceringsår 2017
Publicerad vid Institutionen för neurovetenskap och fysiologi
Institutionen för nationalekonomi med statistik
Sidor 715-720
Språk English
Länkar dx.doi.org/10.1111/ane.12794
Ämnesord cost-effectiveness, narcolepsy, sodium oxybate, quality-of-life, economic consequences, open-label, health, cataplexy, multicenter, hypersomnia, partners, disease, burden, Neurosciences & Neurology
Ämneskategorier Neurovetenskaper

Sammanfattning

Aims and ObjectivesBased on class-I studies, sodium oxybate is regarded as a first-line treatment for both EDS and cataplexy. The cost-effectiveness of sodium oxybate is largely unknown, though. In this study, we estimate the cost-effectiveness of sodium oxybate as treatment for patients with narcolepsy as compared to standard treatment, by calculating incremental cost-effectiveness ratios (cost per quality-adjusted life year, QALY) for patients in a Swedish setting. Materials and MethodsCalculations were performed using a Markov model with a 10-year time horizon. The study population consisted of adult patients treated for narcolepsy with cataplexy. Healthcare utilization and quality-adjusted life years (QALYs) for each treatment alternative were calculated assuming no treatment effect on survival. Sensitivity analyses were performed for treatment effectiveness and healthcare cost parameters. ResultsThe cost per additional quality-adjusted life year was estimated at SEK 563,481. The cost-effectiveness measure was demonstrated to be particularly sensitive to the duration of the relative quality-of-life improvements accruing to patients treated with sodium oxybate. ConclusionsThe estimated cost per additional QALY for the sodium oxybate treatment alternative compared with standard treatment was estimated above the informal Swedish willingness-to-pay threshold (SEK 500,000). The estimated cost per additional QALY obtained here is likely to overestimate the true cost-effectiveness ratio as potentially beneficial effects on productivity of treatment with sodium oxybate were not included (due to lack of data).

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?